| Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis A Shirani, Y Zhao, ME Karim, C Evans, E Kingwell, ML Van Der Kop, ... Jama 308 (3), 247-256, 2012 | 341 | 2012 |
| Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada E Kingwell, M Van der Kop, Y Zhao, A Shirani, F Zhu, J Oger, H Tremlett Journal of Neurology, Neurosurgery & Psychiatry 83 (1), 61-66, 2012 | 204 | 2012 |
| Outcomes and recurrence rates in chronic subdural haematoma A Amirjamshidi, M Abouzari, B Eftekhar, A Rashidi, J Rezaii, K Esfandiari, ... British journal of neurosurgery 21 (3), 272-275, 2007 | 143 | 2007 |
| Characterising aggressive multiple sclerosis S Menon, A Shirani, Y Zhao, J Oger, A Traboulsee, MS Freedman, ... Journal of Neurology, Neurosurgery & Psychiatry 84 (11), 1192-1198, 2013 | 110 | 2013 |
| Therapeutic advances and future prospects in progressive forms of multiple sclerosis A Shirani, DT Okuda, O Stüve Neurotherapeutics 13 (1), 58-69, 2016 | 99 | 2016 |
| Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort ME Karim, P Gustafson, J Petkau, Y Zhao, A Shirani, E Kingwell, C Evans, ... American journal of epidemiology 180 (2), 160-171, 2014 | 81 | 2014 |
| Antimicrobial resistance pattern of Gram-negative bacilli of nosocomial origin at 2 university hospitals in Iran A Hadadi, M Rasoulinejad, Z Maleki, M Yonesian, A Shirani, Z Kourorian Diagnostic microbiology and infectious disease 60 (3), 301-305, 2008 | 76 | 2008 |
| Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression P Lourenco, A Shirani, J Saeedi, J Oger, WE Schreiber, H Tremlett Multiple Sclerosis Journal 19 (5), 577-584, 2013 | 70 | 2013 |
| Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment A Shirani, Y Zhao, J Petkau, P Gustafson, ME Karim, C Evans, E Kingwell, ... BioMed research international 2015, 2015 | 66 | 2015 |
| Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975–2009) A Shirani, Y Zhao, E Kingwell, P Rieckmann, H Tremlett Multiple Sclerosis Journal 18 (4), 442-450, 2012 | 66 | 2012 |
| Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies ME Karim, P Gustafson, J Petkau, H Tremlett, ... American journal of epidemiology 184 (4), 325-335, 2016 | 61 | 2016 |
| Evaluating the safety of β-interferons in MS: a series of nested case-control studies HJI De Jong, E Kingwell, A Shirani, JW Cohen Tervaert, R Hupperts, ... Neurology 88 (24), 2310-2320, 2017 | 55 | 2017 |
| Beta‐interferon exposure and onset of secondary progressive multiple sclerosis T Zhang, A Shirani, Y Zhao, ME Karim, P Gustafson, J Petkau, C Evans, ... European Journal of Neurology 22 (6), 990-1000, 2015 | 46 | 2015 |
| The effect of smoking on the symptoms and progression of multiple sclerosis: a review A Shirani, H Tremlett Journal of inflammation research, 115-126, 2010 | 36 | 2010 |
| Finger tapping impairments are highly sensitive for evaluating upper motor neuron lesions A Shirani, BD Newton, DT Okuda BMC neurology 17, 1-8, 2017 | 34 | 2017 |
| Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database NG Caldito, A Shirani, A Salter, O Stuve Multiple Sclerosis Journal 27 (7), 1066-1076, 2021 | 33 | 2021 |
| Natalizumab for multiple sclerosis: a case in point for the impact of translational neuroimmunology A Shirani, O Stüve The Journal of Immunology 198 (4), 1381-1386, 2017 | 33 | 2017 |
| Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials Y Zhang, N Gonzalez Caldito, A Shirani, A Salter, G Cutter, W Culpepper, ... Therapeutic Advances in Neurological Disorders 13, 1756286420969016, 2020 | 30 | 2020 |
| Serum prolactin level in patients with multiple sclerosis: a case control study. MH Harirchian, MA Sahraian, A Shirani Medical Science Monitor: International Medical Journal of Experimental and …, 2006 | 30 | 2006 |
| Effect of early interferon beta‐1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event H Pakdaman, MA Sahraian, A Fallah, R Pakdaman, K Ghareghozli, ... Acta Neurologica Scandinavica 115 (6), 429-431, 2007 | 28 | 2007 |
Helen TremlettUniversity of British ColumbiaE-mail megerősítve itt: ubc.ca
